Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective randomized study for the comparison of adding adefovir dipivoxil and switching to entecavir in patients with lamivudine-resistant chronic hepatitis B.

Trial Profile

Prospective randomized study for the comparison of adding adefovir dipivoxil and switching to entecavir in patients with lamivudine-resistant chronic hepatitis B.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Feb 2013

At a glance

  • Drugs Adefovir dipivoxil (Primary) ; Entecavir; Lamivudine
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Acronyms ACE
  • Most Recent Events

    • 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Dec 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 23 Dec 2011 Planned End Date changed from 1 Dec 2010 to 1 Feb 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top